MCRM
RNXT icon

Midway Capital Research & Management’s RenovoRx RNXT Stock Holding History

Midway Capital Research & Management’s Portfolio RNXT Stock Details RNXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.17K Hold
6,300
– – ﹤0.01% 100
2026
Q1 		$6.36K Buy
+6,300
New +$6.1K 0.01% 101

Other funds holding RNXT

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
CPIG
Chicago Partners Investment Group Chicago, Illinois $5B AUM 26.84% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $187B AUM 21.7% 1-Year Est. Return

Midway Capital Research & Management's RNXT Position: Q2 2026 in Review

Midway Capital Research & Management held its RenovoRx (RNXT) position steady in Q2 2026 at 6,300 shares worth $6.17K. The position accounts for ﹤0.01% of the portfolio, ranked #100.

Midway Capital Research & Management first reported a position in RNXT in Q1 2026 and has held it in 2 quarters since. The position peaked at $6.36K in Q1 2026. 28 funds tracked by Wall St. Rank hold RNXT as of Q2 2026.

  • Midway Capital Research & Management held 6,300 shares of RenovoRx worth $6.17K as of Q2 2026.
  • Midway Capital Research & Management left its RenovoRx share count unchanged in Q2 2026.
  • RenovoRx made up ﹤0.01% of Midway Capital Research & Management's portfolio in Q2 2026, its #100 holding.
  • Midway Capital Research & Management first reported a position in RenovoRx in Q1 2026 and has held it in 2 quarters since.
  • Midway Capital Research & Management's RenovoRx position peaked at $6.36K in Q1 2026.
  • 28 funds tracked by Wall St. Rank held RenovoRx as of Q2 2026.

Based on Midway Capital Research & Management's 13F filing for Q2 2026, filed 14 Jul 2026.